Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
NCT07159204 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-09-08
Summary
After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
Conditions
- Biliary Tract Cancer (BTC)
Interventions
- DRUG
-
Paclitaxel polymer micelle immunocombination
Paclitaxel polymer micelle immunocombination
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-01
- Primary Completion
- 2025-12-31
- Completion
- 2026-07-01
Countries
- China
Study Locations
More Related Trials
-
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
NCT05291052 ·Status: UNKNOWN ·Phase: PHASE2
-
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06956716 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer
NCT02163291 ·Status: UNKNOWN ·Phase: PHASE2
-
Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
NCT07310069 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
NCT06417892 ·Status: RECRUITING
-
Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma
NCT05816863 ·Status: UNKNOWN
-
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
NCT07320586 ·Status: RECRUITING ·Phase: PHASE2
-
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
NCT06773312 ·Status: RECRUITING ·Phase: PHASE1
-
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
NCT05985707 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer
NCT03286244 ·Status: UNKNOWN ·Phase: PHASE1
-
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT05757336 ·Status: RECRUITING ·Phase: PHASE2
-
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
NCT00639522 ·Status: UNKNOWN ·Phase: PHASE1
-
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma
NCT01053390 ·Status: COMPLETED ·Phase: PHASE3
-
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
NCT07156058 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
NCT04258657 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06415669 ·Status: RECRUITING ·Phase: PHASE2
-
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
NCT01167049 ·Status: UNKNOWN ·Phase: PHASE2
-
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
NCT05019677 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
NCT07253896 ·Status: RECRUITING ·Phase: PHASE2
-
Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer
NCT04675866 ·Status: UNKNOWN ·Phase: NA
-
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
NCT01253525 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
NCT06339216 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
NCT03990103 ·Status: UNKNOWN ·Phase: PHASE2
-
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
NCT05812430 ·Status: UNKNOWN ·Phase: PHASE2
-
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
NCT04010071 ·Status: UNKNOWN ·Phase: PHASE2